The role of soluble receptor for advanced glycation end-products (sRAGE) in the general population and patients with diabetes mellitus with a focus on renal function and overall outcome

References

• Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13:1971–1978.
   PubMed Web of Science ®Google Scholar
• Hudson BI, Lippman ME. Targeting RAGE signaling in inflammatory disease. Annu Rev Med. 2018;69:349–364.
   PubMed Web of Science ®Google Scholar
• Loeser RF, Yammani RR, Carlson CS, et al. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum. 2005;52:2376–2385.
   PubMed Web of Science ®Google Scholar
• Maillard-Lefebvre H, Boulanger E, Daroux M, et al. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford). 2009;48:1190–1196.
   PubMed Web of Science ®Google Scholar
• Schmidt AM. Soluble RAGEs – prospects for treating & tracking metabolic and inflammatory disease. Vascul Pharmacol. 2015;72:1–8.
   PubMed Web of Science ®Google Scholar
• Zhang L, Bukulin M, Kojro E, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem. 2008;283:35507–35516.
   PubMed Web of Science ®Google Scholar
• Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22:3716–3727.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington P, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes. 2011;60:2379–2385.
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Brett J, et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest. 1993;91:2155–2168.
   PubMed Web of Science ®Google Scholar
• Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025–1031.
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994;14:1521–1528.
   PubMed Web of Science ®Google Scholar
• Kislinger T, Fu C, Huber B, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740–31749.
   PubMed Web of Science ®Google Scholar
• Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest. 1996;97:238–243.
   PubMed Web of Science ®Google Scholar
• Daborg J, von Otter M, Sjölander A, et al. Association of the RAGE G82S polymorphism with Alzheimer's disease. J Neural Transm (Vienna). 2010;117:861–867.
   PubMed Web of Science ®Google Scholar
• Prasad K. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases? Mol Cell Biochem. 2019;451:139–144.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yan SS, Colgan J, et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol. 2004;173:1399–1405.
   PubMed Web of Science ®Google Scholar
• Zong H, Madden A, Ward M, et al. Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem. 2010;285:23137–23146.
   PubMed Web of Science ®Google Scholar
• Kalousová M, Bartosová K, Zima T, et al. Pregnancy-associated plasma protein A and soluble receptor for advanced glycation end products after kidney transplantation. Kidney Blood Press Res. 2007;30:31–37.
   PubMed Web of Science ®Google Scholar
• Cheng C, Tsuneyama K, Kominami R, et al. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol. 2005;18:1385–1396.
   PubMed Web of Science ®Google Scholar
• Basta G, Leonardis D, Mallamaci F, et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int. 2010;77:225–231.
   PubMed Web of Science ®Google Scholar
• Chayanupatkul M, Honsawek S. Soluble receptor for advanced glycation end products (sRAGE) in plasma and synovial fluid is inversely associated with disease severity of knee osteoarthritis. Clin Biochem. 2010;43:1133–1137.
   PubMed Web of Science ®Google Scholar
• Manichaikul A, Sun L, Borczuk AC, et al. Plasma soluble receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017;14:628–635.
   PubMed Web of Science ®Google Scholar
• Joly P, Marshall JC, Tessier PA, et al. S100A8/A9 and sRAGE kinetic after polytrauma; an explorative observational study. Scand J Trauma Resusc Emerg Med. 2017;25:114.
   PubMed Web of Science ®Google Scholar
• Wu F, Afanasyeva Y, Zeleniuch-Jacquotte A, et al. Temporal reliability of serum soluble and endogenous secretory receptors for advanced glycation end-products (sRAGE and esRAGE) in healthy women. Cancer Causes Control. 2018;29:901–905.
   PubMed Web of Science ®Google Scholar
• Yasuhiko Y, Junnosuke M, Shigeru S, et al. Assaying soluble forms of receptor for advanced glycation end products. Arterioscler Thromb Vasc Biol. 2007;27:e33–e34.
   Web of Science ®Google Scholar
• Brinkley TE, Leng X, Nicklas BJ, et al. Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults. Metab Clin Exp. 2017;70:98–106.
   PubMed Web of Science ®Google Scholar
• Lanati N, Emanuele E, Brondino N, et al. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr Vasc Pharmacol. 2010;8:86–92.
   PubMed Web of Science ®Google Scholar
• Oz Gul O, Tuncel E, Yilmaz Y, et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metab Clin Exp. 2010;59:64–69.
   PubMed Web of Science ®Google Scholar
• Koyama H, Tanaka S, Monden M, et al. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE). Atherosclerosis. 2014;234:329–334.
   PubMed Web of Science ®Google Scholar
• Tam HL, Shiu SWM, Wong Y, et al. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis. 2010;209:173–177.
   PubMed Web of Science ®Google Scholar
• Tan KCB, Chow WS, Tso AWK, et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia. 2007;50:1819–1825.
   PubMed Web of Science ®Google Scholar
• Choi KM, Han KA, Ahn HJ, et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97:3751–3758.
   PubMed Web of Science ®Google Scholar
• Bower JK, Pankow JS, Lazo M, et al. Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). Clin Biochem. 2014;47:132–134.
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Drury S, Hudson BI, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002;3:123–135.
   PubMed Web of Science ®Google Scholar
• Jang Y, Kim JY, Kang SM, et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metab Clin Exp. 2007;56:199–205.
   PubMed Web of Science ®Google Scholar
• Xiong DD, Zhang M, Li N, et al. Mediation of inflammation, obesity and fatty liver disease by advanced glycation endoproducts. Eur Rev Med Pharmacol Sci. 2017;21:5172–5178.
   PubMed Web of Science ®Google Scholar
• Vazzana N, Guagnano MT, Cuccurullo C, et al. Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. J Clin Endocrinol Metab. 2012;97:E1726–E1730.
   PubMed Web of Science ®Google Scholar
• de Giorgis T, D'Adamo E, Giannini C, et al. Could receptors for advanced glycation end products be considered cardiovascular risk markers in obese children? Antioxid Redox Signal. 2012;17:187–191.
   PubMed Web of Science ®Google Scholar
• D'Adamo E, Giannini C, Chiavaroli V, et al. What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children? Antioxid Redox Signal. 2011;14:1167–1172.
   PubMed Web of Science ®Google Scholar
• Chiavaroli V, D'Adamo E, Giannini C, et al. Serum levels of receptors for advanced glycation end products in normal-weight and obese children born small and large for gestational age. Diabetes Care. 2012;35:1361–1363.
   PubMed Web of Science ®Google Scholar
• Gurecká R, Koborová I, Csongová M, et al. Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study. Glycoconj J. 2016;33:599–606.
   PubMed Web of Science ®Google Scholar
• He CT, Lee CH, Hsieh CH, et al. Soluble form of receptor for advanced glycation end products is associated with obesity and metabolic syndrome in adolescents. Int J Endocrinol. 2014;2014:1–7.
   Web of Science ®Google Scholar
• Davis KE, Prasad C, Vijayagopal P, et al. Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults. Nutr Res. 2014;34:478–485.
   PubMed Web of Science ®Google Scholar
• Selvin E, Halushka MK, Rawlings AM, et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 2013;62:2116–2121.
   PubMed Web of Science ®Google Scholar
• Koyama H, Shoji T, Yokoyama H, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:2587–2593.
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metab Clin Exp. 2006;55:1227–1231.
   PubMed Web of Science ®Google Scholar
• Norata GD, Garlaschelli K, Grigore L, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis. 2009;19:129–134.
   PubMed Web of Science ®Google Scholar
• Guclu M, Ali A, Eroglu DU, et al. Serum levels of sRAGE are associated with body measurements, but not glycemic parameters in patients with prediabetes. Metab Syndr Relat Disord. 2016;14:33–39.
   PubMed Web of Science ®Google Scholar
• Dozio E, Briganti S, Delnevo A, et al. Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women. Eur J Nutr. 2017;56:2557–2564.
   PubMed Web of Science ®Google Scholar
• Rowisha M, El-Batch M, El Shikh T, et al. Soluble receptor and gene polymorphism for AGE: relationship with obesity and cardiovascular risks. Pediatr Res. 2016;80:67–71.
   PubMed Web of Science ®Google Scholar
• Miranda ER, Somal VS, Mey JT, et al. Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes. Am J Physiol Endocrinol Metab. 2017;313:E631–E640.
   PubMed Web of Science ®Google Scholar
• Zaki M, Kamal S, Kholousi S, et al. Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in Egyptian obese women. EXCLI J. 2017;16:973–980.
   PubMed Web of Science ®Google Scholar
• Koborová I, Gurecká R, Csongová M, et al. Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and the activity of semicarbazide-sensitive amine oxidase. Croat Med J. 2017;58:106–116.
   PubMed Web of Science ®Google Scholar
• Miranda ER, Fuller KNZ, Perkins RK, et al. Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health. Nutr Metab Cardiovasc Dis. 2018;28:1155–1165.
   PubMed Web of Science ®Google Scholar
• Hudson BI, Gardener H, Liu-Mares W, et al. Serum soluble RAGE levels and carotid atherosclerosis: the Northern Manhattan Study (NOMAS). Atherosclerosis. 2015;240:17–20.
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mohtarin S, Mudi SR, et al. Relationship of soluble RAGE with insulin resistance and beta cell function during development of type 2 diabetes mellitus. J Diabetes Res. 2015;2015:1–6.
   Web of Science ®Google Scholar
• Sebeková K, Krivošíková Z, Gajdoš M. Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects. Clin Chem Lab Med. 2014;52:139–149.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang W, Zhao H, et al. Fasting blood soluble RAGE may be causally implicated in impaired glucose metabolism in Chinese patients with primary hypertension. Gene. 2018;639:11–17.
   PubMed Web of Science ®Google Scholar
• Huang M, Que Y, Shen X. Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients. J Diabetes Complicat. 2015;29:422–426.
   PubMed Web of Science ®Google Scholar
• Di Pino A, Urbano F, Zagami RM, et al. Low endogenous secretory receptor for advanced glycation end-products levels are associated with inflammation and carotid atherosclerosis in prediabetes. J Clin Endocrinol Metab. 2016;101:1701–1709.
   PubMed Web of Science ®Google Scholar
• Di Pino A, Urbano F, Scicali R, et al. 1 h postload glycemia is associated with low endogenous secretory receptor for advanced glycation end product levels and early markers of cardiovascular disease. Cells. 2019;8:910.
   Web of Science ®Google Scholar
• Hagen I, Schulte DM, Müller N, et al. Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. Cytokine. 2015;73:265–269.
   PubMed Web of Science ®Google Scholar
• Haddad M, Knani I, Bouzidi H, et al. Plasma levels of pentosidine, carboxymethyl-lysine, soluble receptor for advanced glycation end products, and metabolic syndrome: the metformin effect. Dis Markers. 2016;2016:6248264.
   PubMed Web of Science ®Google Scholar
• Eleazu C, Omar N, Lim OZ, et al. Obesity and comorbidity: could simultaneous targeting of esRAGE and sRAGE be the panacea? Front Physiol. 2019;10:787.
   PubMed Web of Science ®Google Scholar
• Ha CH, Kim S, Chung J, et al. Inhibitory effect of soluble RAGE in disturbed flow-induced atherogenesis. Int J Mol Med. 2013;32:373–380.
   PubMed Web of Science ®Google Scholar
• Jeong J, Lee J, Lim J, et al. Soluble RAGE attenuates AngII-induced endothelial hyperpermeability by disrupting HMGB1-mediated crosstalk between AT1R and RAGE. Exp Mol Med. 2019;51:1–15.
   Web of Science ®Google Scholar
• Bijnen M, Beelen N, Wetzels S, et al. RAGE deficiency does not affect non-alcoholic steatohepatitis and atherosclerosis in Western type diet-fed Ldlr–/– mice. Sci Rep. 2018;8:15256.
   PubMed Web of Science ®Google Scholar
• Prasad K, Mishra M. Do advanced glycation end products and its receptor play a role in pathophysiology of hypertension? Int J Angiol. 2017;26:1–11.
   PubMed Web of Science ®Google Scholar
• Gryszczyńska B, Budzyń M, Begier-Krasińska B, et al. Association between advanced glycation end products, soluble rage receptor, and endothelium dysfunction, evaluated by circulating endothelial cells and endothelial progenitor cells in patients with mild and resistant hypertension. Int J Mol Sci. 2019;20:3942.
   Web of Science ®Google Scholar
• Maresca AM, Guasti L, Bozzini S, et al. sRAGE and early signs of cardiac target organ damage in mild hypertensives. Cardiovasc Diabetol. 2019;18:17.
   PubMed Web of Science ®Google Scholar
• Chiang KH, Chen JW, Huang SS, et al. The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients. BMC Endocr Disord. 2018;18:84.
   PubMed Web of Science ®Google Scholar
• Gelžinský J, Mayer O, Seidlerová J, et al. Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness. Hypertens Res. 2020;43:111–120.
   PubMed Web of Science ®Google Scholar
• Moriya S, Yamazaki M, Murakami H, et al. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE. J Stroke Cerebrovasc Dis. 2014;23:2540–2546.
   PubMed Web of Science ®Google Scholar
• Lindsey JB, Cipollone F, Abdullah SM, et al. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009;6:7–14.
   PubMed Web of Science ®Google Scholar
• Cecil DL, Terkeltaub RA. Arterial calcification is driven by RAGE in Enpp1–/– mice. J Vasc Res. 2011;48:227–235.
   PubMed Web of Science ®Google Scholar
• Grauen Larsen H, Marinkovic G, Nilsson PM, et al. High plasma sRAGE (soluble receptor for advanced glycation end products) is associated with slower carotid intima-media thickness progression and lower risk for first-time coronary events and mortality. Arterioscler Thromb Vasc Biol. 2019;39:925–933.
   PubMed Web of Science ®Google Scholar
• McNair ED, Wells CR, Qureshi AM, et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol. 2009;18:187–192.
   PubMedGoogle Scholar
• McNair ED, Wells CR, Mabood Qureshi A, et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol. 2010;33:678–685.
   PubMed Web of Science ®Google Scholar
• Pearce C, Islam N, Bryce R, et al. Advanced glycation end products:receptors for advanced glycation end products axis in coronary stent restenosis: a prospective study. Int J Angiol. 2018;27:213–222.
   PubMed Web of Science ®Google Scholar
• Tang SC, Wang YC, Li YI, et al. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol. 2013;33:585–594.
   PubMed Web of Science ®Google Scholar
• Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003;111:959–972.
   PubMed Web of Science ®Google Scholar
• Pullerits R, Brisslert M, Jonsson IM, et al. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum. 2006;54:3898–3907.
   PubMed Web of Science ®Google Scholar
• Fukami K, Yamagishi SI, Okuda S. Role of AGEs–RAGE system in cardiovascular disease. Curr Pharm Des. 2014;20:2395–2402.
   PubMed Web of Science ®Google Scholar
• Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93:1143–1152.
   PubMed Web of Science ®Google Scholar
• Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008;4:285–293.
   PubMedGoogle Scholar
• Linden E, Cai W, He JC, et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol. 2008;3:691–698.
   PubMed Web of Science ®Google Scholar
• Hartog JWL, de Vries APJ, Lutgers HL, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci. 2005;1043:299–307.
   PubMed Web of Science ®Google Scholar
• Semba RD, Ferrucci L, Fink JC, et al. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis. 2009;53:51–58.
   PubMed Web of Science ®Google Scholar
• Rebholz CM, Astor BC, Grams ME, et al. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrol Dial Transplant. 2015;30:77–83.
   PubMed Web of Science ®Google Scholar
• Loomis SJ, Chen Y, Sacks DB, et al. Cross-sectional analysis of AGE-CML, sRAGE, and esRAGE with diabetes and cardiometabolic risk factors in a community-based cohort. Clin Chem. 2017;63:980–989.
   PubMed Web of Science ®Google Scholar
• Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009;7:17.
   PubMed Web of Science ®Google Scholar
• Butcher L, Carnicero JA, Gomez Cabrero D, et al. Increased levels of soluble receptor for advanced glycation end-products (RAGE) are associated with a higher risk of mortality in frail older adults. Age Ageing. 2019;48:696–702.
   PubMed Web of Science ®Google Scholar
• Ho JE, Lyass A, Courchesne P, et al. Protein biomarkers of cardiovascular disease and mortality in the community. J Am Heart Assoc. 2018;7:e008108.
   PubMed Web of Science ®Google Scholar
• Ebert H, Lacruz ME, Kluttig A, et al. Association between advanced glycation end products, their soluble receptor, and mortality in the general population: results from the CARLA study. Exp Gerontol. 2020;131:110815.
   PubMed Web of Science ®Google Scholar
• Salonen KM, Ryhänen SJ, Forbes JM, et al. Circulating concentrations of soluble receptor for AGE are associated with age and AGER gene polymorphisms in children with newly diagnosed type 1 diabetes. Diabetes Care. 2014;37:1975–1981.
   PubMed Web of Science ®Google Scholar
• Salonen KM, Ryhänen SJ, Forbes JM, et al. A drop in the circulating concentrations of soluble receptor for advanced glycation end products is associated with seroconversion to autoantibody positivity but not with subsequent progression to clinical disease in children en route to type 1 diabetes. Diabetes Metab Res Rev. 2017;33:e2872.
   Web of Science ®Google Scholar
• Salonen KM, Ryhänen SJ, Forbes JM, et al. Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes. Diabetes Care. 2015;38:665–670.
   PubMed Web of Science ®Google Scholar
• Dettoraki A, Gil APR, Spiliotis BE. Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2009;22:895–904.
   PubMed Web of Science ®Google Scholar
• Koutroumani N, Partsalaki I, Lamari F, et al. Protective mechanisms against oxidative stress and angiopathy in young patients with diabetes type 1 (DM1). J Pediatr Endocrinol Metab. 2013;26:309–317.
   PubMed Web of Science ®Google Scholar
• Saito R, Araki S, Yamamoto Y, et al. Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children. J Pediatr Endocrinol Metab. 2017;30:63–69.
   PubMed Web of Science ®Google Scholar
• Heier M, Margeirsdottir HD, Gaarder M, et al. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study. Cardiovasc Diabetol. 2015;14:126.
   PubMed Web of Science ®Google Scholar
• Challier M, Jacqueminet S, Benabdesselam O, et al. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem. 2005;51:1749–1750.
   PubMed Web of Science ®Google Scholar
• Skrha J, Kalousová M, Svarcová J, et al. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120:277–281.
   PubMed Web of Science ®Google Scholar
• Miura J, Yamamoto Y, Osawa M, et al. Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol. 2007;27:253–254.
   PubMed Web of Science ®Google Scholar
• Reis JS, Veloso CA, Volpe CMO, et al. Soluble RAGE and malondialdehyde in type 1 diabetes patients without chronic complications during the course of the disease. Diab Vasc Dis Res. 2012;9:309–314.
   PubMed Web of Science ®Google Scholar
• Bakker SF, Tushuizen ME, Gözütok E, et al. Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease. Nutr Metab Cardiovasc Dis. 2015;25:230–235.
   PubMed Web of Science ®Google Scholar
• Lam JKY, Wang Y, Shiu SWM, et al. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet Med. 2013;30:702–709.
   PubMed Web of Science ®Google Scholar
• Katakami N, Matsuhisa M, Kaneto H, et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res. 2008;5:190–197.
   PubMed Web of Science ®Google Scholar
• Sakurai S, Yamamoto Y, Tamei H, et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract. 2006;73:158–165.
   PubMed Web of Science ®Google Scholar
• Škrha J, Muravská A, Flekač M, et al. Fructosamine 3-kinase and glyoxalase I polymorphisms and their association with soluble RAGE and adhesion molecules in diabetes. Physiol Res. 2014;63:S283–S291.
   PubMed Web of Science ®Google Scholar
• Miranda ER, Fuller KNZ, Perkins RK, et al. Divergent changes in plasma AGEs and sRAGE isoforms following an overnight fast in T1DM. Nutrients. 2019;11:386.
   Web of Science ®Google Scholar
• Nin JWM, Ferreira I, Schalkwijk CG, et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia. 2009;52:705–714.
   PubMed Web of Science ®Google Scholar
• Katakami N, Matsuhisa M, Kaneto H, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis. 2009;204:288–292.
   PubMed Web of Science ®Google Scholar
• Klein R, Horak K, Lee KE, et al. The relationship of serum soluble receptor for advanced glycation end products (sRAGE) and carboxymethyl lysine (CML) to the incidence of diabetic nephropathy in persons with type 1 diabetes. Diabetes Care. 2017;40:e117–e119.
   PubMed Web of Science ®Google Scholar
• Wadén JM, Dahlström EH, Elonen N, et al. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes. Diabetologia. 2019;62:1268–1274.
   PubMed Web of Science ®Google Scholar
• Nin JWM, Jorsal A, Ferreira I, et al. Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes. 2010;59:2027–2032.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Söderlund J, Lehto M, et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia. 2011;54:2669–2677.
   PubMed Web of Science ®Google Scholar
• Komulainen J, Kulmala P, Savola K, et al. Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care. 1999;22:1950–1955.
   PubMed Web of Science ®Google Scholar
• Devangelio E, Santilli F, Formoso G, et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med. 2007;43:511–518.
   PubMed Web of Science ®Google Scholar
• Tam XHL, Shiu SWM, Leng L, et al. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in type 2 diabetes. Clin Sci. 2011;120:81–89.
   PubMed Web of Science ®Google Scholar
• Su XD, Li SS, Tian YQ, et al. Elevated serum levels of advanced glycation end products and their monocyte receptors in patients with type 2 diabetes. Arch Med Res. 2011;42:596–601.
   PubMed Web of Science ®Google Scholar
• Yang SJ, Kim S, Hwang SY, et al. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography. Atherosclerosis. 2012;220:402–406.
   PubMed Web of Science ®Google Scholar
• Motawi TM, Abou-Seif MA, Bader AM, et al. Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients. BMC Endocr Disord. 2013;13:32.
   PubMed Web of Science ®Google Scholar
• Renard C, Chappey O, Wautier MP, et al. The human and rat recombinant receptors for advanced glycation end products have a high degree of homology but different pharmacokinetic properties in rats. J Pharmacol Exp Ther. 1999;290:1458–1466.
   PubMed Web of Science ®Google Scholar
• Farhan SS, Hussain SA. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13:2457–2461.
   PubMed Web of Science ®Google Scholar
• Lisowska A, Siergiejko E, Tycińska A, et al. sVCAM-1 concentration and carotid IMT values in patients with acute myocardial infarction-atherosclerotic markers of the presence, progress and prognosis. Adv Med Sci. 2015;60:101–106.
   PubMed Web of Science ®Google Scholar
• Piarulli F, Lapolla A, Ragazzi E, et al. Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients. Atherosclerosis. 2013;226:252–257.
   PubMed Web of Science ®Google Scholar
• Lu L, Pu LJ, Zhang Q, et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis. 2009;206:540–545.
   PubMed Web of Science ®Google Scholar
• Peng WH, Lu L, Hu J, et al. Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients. Clin Biochem. 2009;42:1252–1259.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yamagishi SI, Matsui T, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med. 2007;7:188–190.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yamagishi S, Adachi H, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev. 2007;23:368–371.
   PubMed Web of Science ®Google Scholar
• Fujisawa K, Katakami N, Kaneto H, et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis. 2013;227:425–428.
   PubMed Web of Science ®Google Scholar
• Park HJ, Baek JY, Shin WS, et al. Soluble receptor of advanced glycated endproducts is associated with plaque vulnerability in patients with acute myocardial infarction. Circ J. 2011;75:1685–1690.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yamagishi S, Adachi H, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res. 2008;76:52–56.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yamagishi S, Adachi H, et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev. 2008;24:109–114.
   PubMed Web of Science ®Google Scholar
• Lim SC, Dorajoo R, Zhang X, et al. Genetic variants in the receptor for advanced glycation end products (RAGE) gene were associated with circulating soluble RAGE level but not with renal function among Asians with type 2 diabetes: a genome-wide association study. Nephrol Dial Transplant. 2017;32:1697–1704.
   PubMed Web of Science ®Google Scholar
• Gaens KHJ, Ferreira I, van der Kallen CJH, et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab. 2009;94:5174–5180.
   PubMed Web of Science ®Google Scholar
• KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease; 2013. Available from: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
   Google Scholar
• Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.
   PubMed Web of Science ®Google Scholar
• Kang P, Tian C, Jia C. Association of RAGE gene polymorphisms with type 2 diabetes mellitus, diabetic retinopathy and diabetic nephropathy. Gene. 2012;500:1–9.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Woodward M, Neal B, et al. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. Diabetes Care. 2015;38:1891–1897.
   PubMed Web of Science ®Google Scholar
• Tan KCB, Shiu SWM, Chow WS, et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia. 2006;49:2756–2762.
   PubMed Web of Science ®Google Scholar
• Humpert PM, Djuric Z, Kopf S, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol. 2007;6:9.
   PubMed Web of Science ®Google Scholar
• Humpert PM, Kopf S, Djuric Z, et al. Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care. 2006;29:1111–1113.
   PubMed Web of Science ®Google Scholar
• Sakata K, Hayakawa M, Yano Y, et al. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab Res Rev. 2013;29:624–630.
   PubMed Web of Science ®Google Scholar
• Yu JY, An XF, Liu JS, et al. Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage. Diabetes Res Clin Pract. 2010;87:157–160.
   PubMed Web of Science ®Google Scholar
• Grossin N, Wautier MP, Meas T, et al. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab. 2008;34:392–395.
   PubMed Web of Science ®Google Scholar
• Kalousová M, Hodková M, Kazderová M, et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis. 2006;47:406–411.
   PubMed Web of Science ®Google Scholar
• Gohda T, Tanimoto M, Moon JY, et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract. 2008;81:196–201.
   PubMed Web of Science ®Google Scholar
• Ebihara I, Nakamura T, Shimada N, et al. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1998;32:544–550.
   PubMed Web of Science ®Google Scholar
• Wong FN, Chua KH, Tan J, et al. Glycaemic control in type 2 diabetic patients with chronic kidney disease: the impacts on enzymatic antioxidants and soluble RAGE. PeerJ. 2018;6:e4421.
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia. 2009;52:2251–2263.
   PubMed Web of Science ®Google Scholar
• Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162:1123–1137.
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106:2827–2835.
   PubMed Web of Science ®Google Scholar
• Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23:1725–1729.
   PubMed Web of Science ®Google Scholar
• Dimitriadis K, Tsioufis C, Kasiakogias A, et al. Soluble receptor for advanced glycation end-product levels are related to albuminuria and arterial stiffness in essential hypertension. Nutr Metab Cardiovasc Dis. 2013;23:382–388.
   PubMed Web of Science ®Google Scholar
• Zheng H, Yuan L, Xie N, et al. Association of soluble receptor for advanced glycation end products levels with hypertensive albuminuria. Curr Vasc Pharmacol. 2015;13:259–264.
   PubMed Web of Science ®Google Scholar
• Lindsey JB, de Lemos JA, Cipollone F, et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care. 2009;32:1218–1220.
   PubMed Web of Science ®Google Scholar
• Selejan SR, Linz D, Tatu AM, et al. Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome. J Mol Cell Cardiol. 2018;122:34–46.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001;12:2768–2774.
   PubMed Web of Science ®Google Scholar
• Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92:785–792.
   PubMed Web of Science ®Google Scholar
• Leonardis D, Basta G, Mallamaci F, et al. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis. 2012;22:748–755.
   PubMed Web of Science ®Google Scholar
• Falcone C, Emanuele E, D’Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032–1037.
   PubMed Web of Science ®Google Scholar
• Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 2003;108:1070–1077.
   PubMed Web of Science ®Google Scholar
• Assiri AMA, Kamel HFM, ALrefai AA. Critical appraisal of advanced glycation end products (AGEs) and circulating soluble receptors for advanced glycation end products (sRAGE) as a predictive biomarkers for cardiovascular disease in hemodialysis patients. Med Sci (Basel). 2018;6:38.
   Google Scholar
• Kim JK, Park S, Lee MJ, et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012;220:208–214.
   PubMed Web of Science ®Google Scholar
• Choi BH, Ro H, Jung ES, et al. Circulating S100A12 levels are associated with progression of abdominal aortic calcification in hemodialysis patients. PLoS One. 2016;11:e0150145.
   PubMed Web of Science ®Google Scholar
• Jung ES, Chung W, Kim AJ, et al. Associations between soluble receptor for advanced glycation end products (sRAGE) and S100A12 (EN-RAGE) with mortality in long-term hemodialysis patients. J Korean Med Sci. 2017;32:54–59.
   PubMed Web of Science ®Google Scholar
• Kim HS, Chung W, Kim AJ, et al. Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels. Nephrology (Carlton). 2013;18:777–782.
   PubMed Web of Science ®Google Scholar
• Dozio E, Corradi V, Vianello E, et al. Increased levels of sRAGE in diabetic CKD-G5D patients: a potential protective mechanism against AGE-related upregulation of fibroblast growth factor 23 and inflammation. Mediators Inflamm. 2017;2017:9845175.
   PubMed Web of Science ®Google Scholar
• Dozio E, Ambrogi F, de Cal M, et al. Role of the soluble receptor for advanced glycation end products (sRAGE) as a prognostic factor for mortality in hemodialysis and peritoneal dialysis patients. Mediators Inflamm. 2018;2018:1347432.
   PubMed Web of Science ®Google Scholar
• Boschetto P, Campo I, Stendardo M, et al. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Invest. 2013;43:562–569.
   PubMed Web of Science ®Google Scholar
• Brodska H, Malickova K, Valenta J, et al. Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis. Scand J Clin Lab Invest. 2013;73:650–660.
   PubMed Web of Science ®Google Scholar
• Lancefield TF, Patel SK, Freeman M, et al. The receptor for advanced glycation end products (RAGE) is associated with persistent atrial fibrillation. PLoS One. 2016;11:e0161715.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Welsh P, Papacosta O, et al. Circulating soluble receptor for advanced glycation end product: cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes. Atherosclerosis. 2017;264:36–43.
   PubMed Web of Science ®Google Scholar
• Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, et al. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score. Am J Cardiol. 2011;107:938–944.
   PubMed Web of Science ®Google Scholar
• Nakashima A, Carrero JJ, Qureshi AR, et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:2213–2219.
   PubMed Web of Science ®Google Scholar
• Isoyama N, Leurs P, Qureshi AR, et al. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease stage 5 patients. Nephrol Dial Transplant. 2015;30:84–91.
   PubMed Web of Science ®Google Scholar
• Prasad K, Sarkar A, Zafar MA, et al. Advanced glycation end products and its soluble receptors in the pathogenesis of thoracic aortic aneurysm. Aorta (Stamford). 2016;4:1–10.
   PubMedGoogle Scholar
• Kumar NP, Moideen K, Nancy A, et al. Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy. BMC Infect Dis. 2019;19:1039.
   PubMed Web of Science ®Google Scholar